Novel GLP-1/GIP receptor agonist effective for chronic weight management

Written By : Jacinthlyn Sylvia |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-03-05T05:00:38+05:30 | Updated On 5 March 2024 2:59 PM IST

Viking Therapeutics has unveiled compelling Phase 2 data for their dual GLP-1/GIP receptor agonist, VK2735 for chronic weight management. The VENTURE trial demonstrated promising results and thereby ignites hopes for a new therapeutic option for patients struggling with obesity.

This randomized, double-blind, placebo-controlled study assessed VK2735 across various dosages relative to placebo therapy. Over 13 weeks, 176 patients with obesity or overweight, along with weight-related comorbidities participated in this study. The percent change in body weight from baseline to week 13 was the primary endpoint which was met across all dosage groups.

Also, the patients receiving VK2735 15 mg achieved a remarkable mean placebo-adjusted body weight reduction of 13.1% by week 13, with an impressive 88% of individuals experiencing a placebo-adjusted weight reduction of 10% or more. These results underscore the potential of VK2735 as a game-changer in combating obesity.

The CEO of Viking Therapeutics, expressed enthusiasm over the outcomes of the trial highlighting the promising efficacy and tolerability profile of VK2735. Despite a 20% discontinuation rate among VK2735 recipients, safety analysis revealed mostly mild to moderate drug-related adverse events, with nausea being the most prevalent.

Viking Therapeutics outlined plans for further development of VK2735, including discussions with the FDA and the release of Phase 1 data for an oral formulation of the drug in the upcoming weeks. The CEO affirmed the commitment of the company to advance this vital therapy by signaling optimism for its progression into later clinical stages.

The positive results from the VENTURE trial mark a significant step in the pursuit of effective treatments for obesity and related comorbidities. VK2735 demonstrates promising efficacy and manageable safety profile to address the unmet needs in chronic weight management for patients seeking alternative therapeutic options.

Reference:

Viking therapeutics announces positive top-line results from phase 2 VENTURE trial of dual GLP-1/GIP receptor agonist VK2735 in patients with obesity. (n.d.). Viking Therapeutics InvestorRoom. Retrieved March 1, 2024, from https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity

Viking Therapeuticschronic weight managementGLP-1/GIP receptor agonist

Source : Viking Therapeutics

Jacinthlyn Sylvia

Neuroscience Masters graduate

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751